VERA
Vera Therapeutics, Inc.
$34.26
+1.81%
$2.5B
No data for this timeframe.
Vol
Market Cap$2.5B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders50 funds
Inst. Value$1.4B
Inst. Activity19 buys / 10 sells
Insider Activity0B / 9S
Insider Net $-$2.5M
Reddit Sentiment50° Neutral
SEC Reports11
Press Releases1
Recent Activity
Jul 7, 2026
fda_pdufa
PDUFA: VERA — atacicept in IgA nephropathy (IgAN) — 2026-07-07
FDA target action date 2026-07-07 for VERA (Vera Therapeutics, Inc.). Drug: atacicept. Indication: I
Jun 11, 2026
SEC
Seven institutional investors accumulated $115.7M in VERA during Q3 2025, led by Point72's new $37M position and Citadel
INST-CLUSTER — Impact 6/10
Jun 2, 2026
SEC
Vera Therapeutics announced alignment with the FDA on a revised, earlier ORIGIN 3 eGFR analysis plan for atacicept in Ig
8-K — Impact 7/10
Jun 2, 2026
Press
Vera Therapeutics announced FDA alignment on a revised, earlier eGFR analysis plan for atacicept in IgA Nephropathy, pul
Impact 7/10
May 21, 2026
Insider
ENRIGHT PATRICK G was granted 17,084 shares
Director
May 21, 2026
Insider
MORRISSEY MICHAEL was granted 17,084 shares
Director
May 21, 2026
Insider
Meyers James R was granted 17,084 shares
Director
May 7, 2026
SEC
Vera Therapeutics reported Q1 2026 results with a net loss of $1.69 per share, wider than the $0.81 loss in Q1 2025, dri
8-K — Impact 4/10
Price Targets
$78.00
+127.7% upside
Strong Buy
Current $34.26
Low $35.00
Median $82.00
High $110.00
14 analysts
$35.00
$110.00
Analyst Ratings
7Strong Buy
11Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 15, 2026 | Evercore ISI Group | MAINTAIN | Outperform → Outperform |
| Mar 11, 2026 | Wolfe Research | UPGRADE | Peer Perform → Outperform |
| Mar 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Dec 19, 2025 | B of A Securities | MAINTAIN | Buy → Buy |
| Dec 19, 2025 | Goldman Sachs | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.71 ▼ -20.0% | $-1.96 — $-1.54 | -43% YoY | 6 |
| Next Q | $-1.64 ▼ -17.6% | $-2.08 — $-1.23 | -30% YoY | 6 |
| Current FY | $-6.29 ▼ -19.6% | $-7.39 — $-5.56 | -35% YoY | 8 |
| Next FY | $-3.80 ▼ -24.9% | $-5.40 — $-2.08 | 40% YoY | 8 |
Latest Reports
BULLISH
INST-CLUSTER
6/10
Seven institutional investors accumulated $115.7M in VERA during Q3 2025, led by Point72's new $37M position and Citadel
Jun 11, 2026
BULLISH
8-K
7/10
Vera Therapeutics announced alignment with the FDA on a revised, earlier ORIGIN 3 eGFR analysis plan for atacicept in Ig
Jun 2, 2026
BULLISH
Press
7/10
Vera Therapeutics announced FDA alignment on a revised, earlier eGFR analysis plan for atacicept in IgA Nephropathy, pul
Jun 2, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| NOMURA ASSET MANAGEMENT CO | — | — |
| Avoro Capital Advisors LLC | $236.9M | — |
| BlackRock, Inc. | $204.7M | — |
| STATE STREET CORP | $135.3M | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $108.0M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 21, 2026 | ENRIGHT PATRICK | A | $0.00 |
| May 21, 2026 | MORRISSEY MICHAEL | A | $0.00 |
| May 21, 2026 | Meyers James | A | $0.00 |
| May 21, 2026 | Hall Kimball | A | $0.00 |
| May 21, 2026 | SEIDENBERG BETH | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
50 institutional holders with $1.4B total value (34,855,294 shares) as of 2026-Q1. Top holders: NOMURA, Avoro, BlackRock,. Net buying activity: 19 institutions added/increased vs 10 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | NOMURA ASSET MANAGEMENT CO LTD | — | $0.00 | 0.0% | — |
| 2 | Avoro Capital Advisors LLC | 5,888,888 | $236.9M | 16.7% | — |
| 3 | BlackRock, Inc. | 5,088,102 | $204.7M | 14.5% | — |
| 4 | STATE STREET CORP | 3,363,638 | $135.3M | 9.6% | ADD +25.7% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 2,683,607 | $108.0M | 7.6% | — |
| 6 | FMR LLC | 2,676,422 | $107.7M | 7.6% | — |
| 7 | ALLIANCEBERNSTEIN L.P. | 1,314,242 | $66.6M | 4.7% | NEW |
| 8 | Point72 Asset Management, L.P. | 1,210,725 | $48.7M | 3.4% | TRIM -30.4% |
| 9 | GOLDMAN SACHS GROUP INC | 1,133,969 | $45.6M | 3.2% | — |
| 10 | Pictet Asset Management Holding SA | 1,051,583 | $42.3M | 3.0% | — |
| 11 | Woodline Partners LP | 1,001,037 | $40.3M | 2.8% | ADD +35.6% |
| 12 | BANK OF AMERICA CORP /DE/ | 589,684 | $23.7M | 1.7% | ADD +41.6% |
| 13 | VANGUARD PORTFOLIO MANAGEMENT LLC | 552,971 | $22.2M | 1.6% | — |
| 14 | FRONTIER CAPITAL MANAGEMENT CO LLC | 551,493 | $22.2M | 1.6% | ADD +48.6% |
| 15 | DEUTSCHE BANK AG\ | 532,466 | $21.4M | 1.5% | ADD +53.3% |
| 16 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 524,562 | $21.1M | 1.5% | — |
| 17 | SCHRODER INVESTMENT MANAGEMENT GROUP | 484,381 | $18.5M | 1.3% | DOUBLED +1424.2% |
| 18 | RENAISSANCE TECHNOLOGIES LLC | 457,300 | $18.4M | 1.3% | DOUBLED +136.5% |
| 19 | VANGUARD FIDUCIARY TRUST CO | 441,511 | $17.8M | 1.3% | — |
| 20 | CITADEL ADVISORS LLC | 429,761 | $17.3M | 1.2% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| STATE STREET CORP | ADD | 2,676,600 | 3,363,638 | +25.7% | $135.3M | 2026-Q1 |
| Point72 Asset Management, L.P. | TRIM | 1,738,385 | 1,210,725 | -30.4% | $48.7M | 2026-Q1 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | ADD | 371,151 | 551,493 | +48.6% | $22.2M | 2026-Q1 |
| DEUTSCHE BANK AG\ | ADD | 347,426 | 532,466 | +53.3% | $21.4M | 2026-Q1 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | DOUBLED | 31,779 | 484,381 | +1424.2% | $18.5M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 193,400 | 457,300 | +136.5% | $18.4M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 54,327 | 419,570 | +672.3% | $16.9M | 2026-Q1 |
| Nuveen, LLC | ADD | 227,081 | 398,602 | +75.5% | $16.0M | 2026-Q1 |
| MORGAN STANLEY | TRIM | 499,665 | 368,760 | -26.2% | $14.8M | 2026-Q1 |
| ExodusPoint Capital Management, LP | DOUBLED | 72,741 | 317,351 | +336.3% | $12.8M | 2026-Q1 |
| VOYA INVESTMENT MANAGEMENT LLC | TRIM | 418,963 | 290,476 | -30.7% | $11.7M | 2026-Q1 |
| TD ASSET MANAGEMENT INC | TRIM | 325,564 | 193,994 | -40.4% | $7.8M | 2026-Q1 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | TRIM | 207,968 | 146,189 | -29.7% | $5.9M | 2026-Q1 |
| Trexquant Investment LP | ADD | 50,055 | 86,685 | +73.2% | $3.5M | 2026-Q1 |
| WELLINGTON MANAGEMENT GROUP LLP | DOUBLED | 21,233 | 59,856 | +181.9% | $2.4M | 2026-Q1 |
| Invesco Ltd. | TRIM | 89,851 | 58,714 | -34.7% | $2.4M | 2026-Q1 |
| Russell Investments Group, Ltd. | TRIM | 124,866 | 51,161 | -59.0% | $2.1M | 2026-Q1 |
| Legal & General Group Plc | TRIM | 46,426 | 33,958 | -26.9% | $1.4M | 2026-Q1 |
| VICTORY CAPITAL MANAGEMENT INC | ADD | 14,766 | 20,969 | +42.0% | $843.6K | 2026-Q1 |
| JANUS HENDERSON GROUP PLC | ADD | 13,935 | 17,658 | +26.7% | $710.3K | 2026-Q1 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | TRIM | 28,323 | 16,931 | -40.2% | $681.1K | 2026-Q1 |
| SEI INVESTMENTS CO | DOUBLED | 6,069 | 13,001 | +114.2% | $523.0K | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | DOUBLED | 912 | 8,456 | +827.2% | $340.2K | 2026-Q1 |
| XPONANCE LLC | ADD | 4,359 | 5,689 | +30.5% | $228.9K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 192 | 1,825 | +850.5% | $73.4K | 2026-Q1 |
17 unique insiders with 35 transactions. Net insider value: -$2.5M ($0.00 bought, $2.5M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 21, 2026 | ENRIGHT PATRICK G | Director | AWARD | 17,084 | — | — |
| May 21, 2026 | MORRISSEY MICHAEL | Director | AWARD | 17,084 | — | — |
| May 21, 2026 | Meyers James R | Director | AWARD | 17,084 | — | — |
| May 21, 2026 | Hall Kimball | Director | AWARD | 17,084 | — | — |
| May 21, 2026 | SEIDENBERG BETH C | Director | AWARD | 17,084 | — | — |
| May 21, 2026 | Oliger Christy J. | Director | AWARD | 17,084 | — | — |
| May 21, 2026 | Cheng Andrew | Director | AWARD | 17,084 | — | — |
| May 21, 2026 | Morrison Scott W | Director | AWARD | 17,084 | — | — |
| May 12, 2026 | Fordyce Marshall | PRESIDENT AND CEO | SELL | 14,219 | $36.64 | $521.0K |
| Apr 14, 2026 | Fordyce Marshall | PRESIDENT AND CEO | SELL | 14,130 | $43.66 | $617.0K |
| Mar 23, 2026 | Wright-Mitchell Jane | Chief Legal Officer | AWARD | 42,403 | — | — |
| Mar 23, 2026 | Wright-Mitchell Jane | Chief Legal Officer | AWARD | 56,850 | — | — |
| Mar 13, 2026 | Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR | EXERCISE | 10,000 | $3.94 | $39.4K |
| Mar 5, 2026 | Hite Christopher | Director | AWARD | 24,937 | — | — |
| Feb 23, 2026 | Skelton Laurence Matthew | Chief Commercial Officer | SELL | 1,582 | $41.98 | $66.4K |
| Feb 23, 2026 | Turner William D. | Chief Regulatory Officer | SELL | 2,187 | $41.98 | $91.8K |
| Feb 23, 2026 | JOHNSON DAVID LEE | Chief Operating Officer | SELL | 2,579 | $41.98 | $108.3K |
| Feb 23, 2026 | Brenner Robert | Chief Medical Officer | SELL | 2,151 | $41.98 | $90.3K |
| Feb 23, 2026 | Grant Sean | CHIEF FINANCIAL OFFICER | SELL | 4,949 | $41.98 | $207.8K |
| Feb 23, 2026 | Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR | SELL | 3,117 | $41.98 | $130.9K |
| Feb 23, 2026 | Fordyce Marshall | PRESIDENT AND CEO | SELL | 16,925 | $41.98 | $710.6K |
| Feb 4, 2026 | Turner William D. | Chief Regulatory Officer | AWARD | 25,000 | — | — |
| Feb 4, 2026 | Skelton Laurence Matthew | Chief Commercial Officer | AWARD | 40,000 | — | — |
| Feb 4, 2026 | Skelton Laurence Matthew | Chief Commercial Officer | AWARD | 20,000 | — | — |
| Feb 4, 2026 | Turner William D. | Chief Regulatory Officer | AWARD | 50,000 | — | — |
| Feb 4, 2026 | Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR | AWARD | 10,000 | — | — |
| Feb 4, 2026 | Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR | AWARD | 20,000 | — | — |
| Feb 4, 2026 | Fordyce Marshall | PRESIDENT AND CEO | AWARD | 68,800 | — | — |
| Feb 4, 2026 | Fordyce Marshall | PRESIDENT AND CEO | AWARD | 137,500 | — | — |
| Feb 4, 2026 | Grant Sean | CHIEF FINANCIAL OFFICER | AWARD | 25,000 | — | — |
| Feb 4, 2026 | Grant Sean | CHIEF FINANCIAL OFFICER | AWARD | 50,000 | — | — |
| Feb 4, 2026 | JOHNSON DAVID LEE | Chief Operating Officer | AWARD | 20,000 | — | — |
| Feb 4, 2026 | JOHNSON DAVID LEE | Chief Operating Officer | AWARD | 40,000 | — | — |
| Feb 4, 2026 | Brenner Robert | Chief Medical Officer | AWARD | 25,000 | — | — |
| Feb 4, 2026 | Brenner Robert | Chief Medical Officer | AWARD | 50,000 | — | — |
11 SEC filing reports analyzed. Sentiment: 2 bullish, 7 bearish, 1 mixed, 1 neutral. Avg impact: 6.4/10.
BULLISH
INST-CLUSTER
6/10
Seven institutional investors accumulated $115.7M in VERA during Q3 2025, led by Point72's new $37M
Jun 11, 2026
BULLISH
8-K
7/10
Vera Therapeutics announced alignment with the FDA on a revised, earlier ORIGIN 3 eGFR analysis plan
Jun 2, 2026
NEUTRAL
8-K
4/10
Vera Therapeutics reported Q1 2026 results with a net loss of $1.69 per share, wider than the $0.81
May 7, 2026
MIXED
8-K
7/10
Vera Therapeutics reported strong business progress with positive Phase 3 data for atacicept in IgA
Feb 26, 2026
BEARISH
CLUSTER
8/10
Seven corporate insiders at Vera Therapeutics, including the CEO, CFO, and other C-suite executives,
Feb 26, 2026
BEARISH
CLUSTER
8/10
Seven executives at Vera Therapeutics, including the CEO, CFO, and other C-suite officers, collectiv
Feb 26, 2026
BEARISH
CLUSTER
5/10
Seven executives at Vera Therapeutics, including the CEO and CFO, collectively sold over $1.4 millio
Feb 26, 2026
BEARISH
CLUSTER
7/10
Five executive officers at Vera Therapeutics, including the CEO and CFO, collectively sold over $1.2
Feb 26, 2026
BEARISH
CLUSTER
7/10
Four C-suite executives at Vera Therapeutics — including CEO Fordyce Marshall — sold shares in a coo
Feb 26, 2026
BEARISH
CLUSTER
6/10
Three senior executives at Vera Therapeutics — the Chief Regulatory Officer, Chief Operating Officer
Feb 26, 2026
BEARISH
CLUSTER
5/10
Two C-suite executives at Vera Therapeutics — the Chief Regulatory Officer and Chief Commercial Offi
Feb 26, 2026
Current analyst consensus: Strong Buy (90% buy). Based on 20 analysts: 7 strong buy, 11 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$78.00 mean target
+127.7% upside
Strong Buy (1.21)
$35.00 Low
$110.00 High
| Metric | Value |
|---|---|
| Current Price | $34.26 |
| Target Low | $35.00 |
| Target Mean | $78.00 |
| Target Median | $82.00 |
| Target High | $110.00 |
| # Analysts | 14 |
| Recommendation | Strong Buy (1.21) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.71 | $-1.96 | $-1.54 | -42.6% | -20.0% | 0↑ 4↓ | $0.0B | 0.0% | 6 |
| Next Q 2026-09-30 |
$-1.64 | $-2.08 | $-1.23 | -30.0% | -17.6% | 0↑ 4↓ | $0.0B | 0.0% | 6 |
| Current FY 2026-12-31 |
$-6.29 | $-7.39 | $-5.56 | -34.9% | -19.6% | 0↑ 8↓ | $0.0B | 0.0% | 8 |
| Next FY 2027-12-31 |
$-3.80 | $-5.40 | $-2.08 | 39.6% | -24.9% | 2↑ 6↓ | $0.3B | 566.8% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.711 | |
| 7d ago | $-1.711 | |
| 30d ago | $-1.426 | -0.285 |
| 60d ago | $-1.426 | -0.285 |
| 90d ago | $-1.475 | -0.236 |
6 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 15, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Mar 11, 2026 | Wolfe Research | UPGRADE | Peer Perform | Outperform |
| Mar 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 19, 2025 | B of A Securities | MAINTAIN | Buy | Buy |
| Dec 19, 2025 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Dec 19, 2025 | JP Morgan | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 11 | 2 | 0 | 0 | 90% | |
| May 1, 2026 | 7 | 11 | 2 | 0 | 0 | 90% | |
| Apr 1, 2026 | 7 | 11 | 2 | 0 | 0 | 90% | |
| Mar 1, 2026 | 6 | 11 | 3 | 0 | 0 | 85% | |
| Feb 1, 2026 | 6 | 11 | 3 | 0 | 0 | 85% | |
| Jan 1, 2026 | 6 | 11 | 3 | 0 | 0 | 85% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
1 mentions
0 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 9, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
Jul 7, 2026
fda_pdufa
PDUFA: VERA — atacicept in IgA nephropathy (IgAN) — 2026-07-07
FDA target action date 2026-07-07 for VERA (Vera Therapeutics, Inc.). Drug: atacicept. Indication: IgA nephropathy (IgAN). FDA assigned a PDUFA target
Jun 5, 2026
other
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 4, 2026
short_volume
Short Volume: VERA — 59.7% short (0.7M / 1.2M)
Short: 730,359 | Exempt: 120 | TRF Vol: 1,223,742 | Short Ratio: 59.7% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
Clinical Trial
Monthly Dosing of Atacicept in IgAN
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Jun 3, 2026
clinical_trial_readout
T-90d Trial Readout: Atacicept (Phase 2)
Trial: Monthly Dosing of Atacicept in IgAN
Sponsor: Vera Therapeutics, Inc.
Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITING
Conditions: IgA Nephropathy
Jun 2, 2026
fda
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with
May 28, 2026
short_volume
Short Volume: VERA — 72.5% short (0.5M / 0.7M)
Short: 535,678 | Exempt: 0 | TRF Vol: 738,700 | Short Ratio: 72.5% | Off-exchange volume (dark pool + OTC)
May 8, 2026
other
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 7, 2026
earnings
Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
May 4, 2026
earnings_calendar
VERA Q1 2026 Earnings Scheduled — 2026-05-04
Apr 28, 2026
short_volume
Short Volume: VERA — 57.0% short (0.5M / 0.8M)
Short: 456,480 | Exempt: 0 | TRF Vol: 800,174 | Short Ratio: 57.0% | Off-exchange volume (dark pool + OTC)
Apr 10, 2026
other
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 1, 2026
short_volume
Short Volume: VERA — 64.7% short (0.3M / 0.5M)
Short: 331,174 | Exempt: 7,821 | TRF Vol: 511,762 | Short Ratio: 64.7% | Off-exchange volume (dark pool + OTC)
Mar 27, 2026
other
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics announces inducement grants Under Nasdaq Listing Rule 5635(c)(4).
Mar 25, 2026
other
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
Mar 23, 2026
short_volume
Short Volume: VERA — 63.0% short (0.5M / 0.8M)
Short: 473,069 | Exempt: 3,000 | TRF Vol: 751,388 | Short Ratio: 63.0% | Off-exchange volume (dark pool + OTC)